Get the Stockscreener App
89.59
2.59%
-2.52
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $89.59, with a volume of 1.77M.
It is down -2.59% in the last 24 hours and up +1.75% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$92.11
Open:
$90.5
24h Volume:
1.77M
Relative Volume:
0.14
Market Cap:
$156.07B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
24.96
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
-6.38%
1M Performance:
+1.75%
6M Performance:
-28.22%
1Y Performance:
-32.04%
1-Day Range:
$88.62
$90.50
1-Week Range:
$88.62
$96.19
52-Week Range:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
89.60 | 160.44B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
310.65 | 127.06B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.11 | 106.97B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
42.90 | 66.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.03 | 52.85B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories To Go Ex-Dividend On July 15th, 2026 With 0.63 USD Dividend Per Share - 富途牛牛
Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights - GlobeNewswire Inc.
Rick Larsen makes multiple trades in Abbott Laboratories, Amphenol Corporation and others - Investing.com Nigeria
Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap? - 24/7 Wall St.
Trump Admin Stopped Criminal Charges Against Abbott Nutrition for Infant Formula Illnesses - Food Safety Magazine
Abbott Laboratories Stock (ABT) Opinions on Diagnostic Advancements and Earnings Trends - Quiver Quantitative
Abbott Laboratories Q2 2026 Earnings Preview — July 16, Street Expects $1.28 EPS - AlphaStreet
Abbott Laboratories stock holds steady as a defensive health care name - Ad Hoc News
Baird Initiates Coverage on Abbott Laboratories (ABT) Stock with Outperform Rating - Yahoo Finance
3 US Healthcare Stocks Investors May Revisit As Inflation Pressures Build - simplywall.st
Healthcare Stocks: J&J, UnitedHealth, Abbott Face Test on Sector’s 9% Earnings Drop - TechStock²
Abbott stock holds steady as its diagnostics business anchors the outlook. - ad-hoc-news.de
Abbott (ABT) Stock Still Looks Cheap On Cash Flow And Earnings - simplywall.st
Richard Dean Dr McCormick of GA06 Makes Multiple Trades, Including Abbott Laboratories and Intercontinental Exchange - Investing.com Nigeria
A Senator Finally Asks the Question I've Been Asking: Where Did the Abbott Criminal Case Go? - Marler Blog
Abbott Labs Vs. Danaher: Abbott’s Everyday Products Beat Danaher’s Slumping Biotech Equipment - AOL.com
symbol__ Stock Quote Price and Forecast - CNN
Abbott Laboratories stock holds steady as healthcare demand supports long-term growth - ad-hoc-news.de
Dividend Roundup: Costco, Phillips 66, Abbott Labs, AbbVie, and more (DVY:NASDAQ) - Seeking Alpha
Dividend Powerhouse: Abbott Laboratories (NYSE:ABT) Passes the Test for Sustainable Income - ChartMill
Probe of Alibaba unearthed evidence it knowingly let dangerous drugs be sold to U.S. consumers — but DOJ did not prosecute - CBS News
Schiff launches inquiry into DOJ's closure of probe into Abbott Labs over bacterial contamination at baby formula plant - CBS News
Abbott Laboratories stock stays supported by diversified health-care business - Ad Hoc News
The Company Accused of Poisoning Baby Formula Gave Trump $500,000. Then the Criminal Case Was Dropped. - Yahoo
Abbott Laboratories stock may move 4.5% on earnings release By Investing.com - Investing.com Canada
Abbott Laboratories stock may move 4.5% on earnings release - Investing.com
ABBOTT LABORATORIES: TURNING BIG IDEAS INTO ACTIONABLE PLANS - McDermott Will & Schulte
Abbott Laboratories highlights diagnostics and medical devices as investors assess long-term growth - AD HOC NEWS
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Abbott Laboratories (ABT) Q1 Sales And Guidance Put Fair Value Back In Focus - Yahoo Finance
Abbott Laboratories balances diagnostics demand and investor expectations - Ad-hoc-news.de
Is Abbott Laboratories (ABT) Stock Still a Healthcare Growth Opportunity After Analyst Target Cut? - Insider Monkey
FreeStyle Libre 3 Sensor from Abbott Laboratoriesdiscreet glucose tracking for active diabetes pa - AD HOC NEWS
Is Abbott Laboratories (ABT) Undervalued After Its Glucose Monitoring Growth Narrative? - simplywall.st
Abbott (ABT) Has a Multi-Platform Device-and-Diagnostics Engine Bigger Than the Libre Narrative - AlphaStreet
Abbott Labs Is Maintained at Outperform by Evercore ISI Group - Moomoo
Evercore Maintains Abbott Laboratories(ABT.US) With Buy Rating, Cuts Target Price to $112 - Moomoo
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Evercore ISI Adjusts Abbott Laboratories Price Target to $112 From $120 - Moomoo
Abbott Laboratories (ABT) Stock Analysis: A Healthcare Giant with a 22.35% Upside Potential - DirectorsTalk Interviews
DOJ Closing Abbott Labs Case Spurs Wider Corporate Crime Retreat - Bloomberg Law News
Abbott Laboratories Stock (ABT) Opinions on Recent FDA Approvals and Product Launches - Quiver Quantitative
Abbott Labs must face lawsuit over PediaSure children's growth claims - MSN
Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering - Seeking Alpha
Abbott Laboratories (NYSE:ABT) Passes the Caviar Cruise Quality Screen with Strong Growth and Profitability - ChartMill
Is Index Shuffle And Probe Shift Reshaping The Investment Case For Abbott Laboratories (ABT)? - simplywall.st
DOJ ends investigation into infant formula company linked to deadly cronobacter outbreak - foodsafetynews.com
Abbott Laboratories (ABT) Shares Surge 3.5% -- What GF Score of 80 Tells Investors - GuruFocus
Missouri jury sides with Enfamil maker Mead Johnson in case over preterm baby formula - Reuters
Trump Loaded Up on Abbott Laboratories Stock Before His DOJ Dropped Criminal Probe - Common Dreams
A Mom Said Infant Formula Killed Her Baby. The Manufacturer Closed the File. - KFF Health News
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.29%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):